fda bpc-157 category 2 compounding Repost @peptides with @use.repost ・・・ BREAKING NEWS! Today's 8–6 advisory vote for is one of the biggest peptide regulatory developments we've seen in years. While nothing changes immediately, the recommendation represents FDA's Overreach on Compounded Peptides

Among them, the cytosolic enzyme nicotinamide N-methyltransferase (NNMT) has been newly discovered to regulate the levels of nicotinamide precursors required for NAD+ biosynthesis, and therefore plays a crucial role in regulating the NAD+ salvage pathway and cellular metabolism

For comprehensive information on peptide side effect profiles in research contexts, see our peptide side effects guide

5-Amino-1MQ targets the substrate binding site of NNMT the nicotinamide binding pocket competitively inhibiting nicotinamide methylation with an IC50 of 1.2 M under reference assay conditions

Furthermore, its highly corrosive nature introduces increased operational safety risks